Reggie Gaudino

As Chief Science Officer at Steep Hill, Dr. Gaudino is building the company’s YnsightTM genetic analysis division
as a companion to Steep Hill’s successful chemical profiling and chemical testing business. Dr. Gaudino is
internationally recognized in the field of cannabis genetics and was featured for his groundbreaking work in
April 2016 in Wired Magazine http://www.wired.com/2016/04/the-science-of-marijuana/.

He is building a team to produce the highest quality scientific results suitable for peer review in the field of
cannabis research. Steep Hill will bring these scientific advancements to market for growers, breeders, and
ultimately consumers. Dr. Gaudino also oversees the day-to-day scientific operations of Steep Hill’s
laboratories in California, New Mexico and Washington, and manages scientific standards for Steep Hill’s
licensees in Alaska, Hawaii, Maryland, DC, Pennsylvania and Arkansas. He also manages scientific
partnerships for joint ventures in Israel and Jamaica, as well as identifying and creating new scientific
partnerships. In addition, Dr. Gaudino identifies new intellectual property (IP) opportunities and protects
existing Steep Hill IP, through aggressive patent and trademark filing.

Dr. Gaudino also is the Scientific Advisor for partner company, Pathogendx, where he helps identify and
commercialize DNA based testing opportunities in the Cannabis Industry. Dr. Gaudino and Steep Hill act as
the partner laboratory for Pathogendx product development and validation testing. Dr. Gaudino also is
currently advising additional Cannabis companies, from both a scientific and intellectual property
perspective. Prior to his role at Steep Hill, Dr. Gaudino served as a published genetic researcher with 18 years
of intellectual property experience in writing, prosecuting and managing patents and patent portfolios in
fields as diverse as software and telecom to biotechnology and molecular genetics. Dr. Gaudino came to Steep
Hill from Sequenom, Inc. (NASDAQ: SQNM) where he served as the Senior Patent Agent. Previously, Dr.
Gaudino managed IP based acquisitions for the Vortice Research Group, and he also has worked at several
law firms such as Grant Anderson LLP, Biotechnology Law Group, Gray Cary Ware & Freidenrich and Lyon &
Lyon, in addition to serving as an advisor and consultant to portfolio investment companies.

Dr. Gaudino received his B.S. in Molecular Biology and Ph.D. in Molecular Genetics from the State University of
New York at Buffalo, and he conducted four years of post-doctoral research at the Washington University in
St. Louis, studying transcriptional regulation of rRNA.